AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Preliminary phase I data of PER.C6-derived HIV vaccine encouraging.(Brief Article)
2002 APR 10 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell N.V. (CRXL) said initial data from a phase I trial involving Merck & Co., Inc.'s, experimental HIV vaccine look encouraging. The HIV vaccine, based on a recombinant adenovirus, is produced on Crucell's proprietary PER.C6 cell technology platform to facilitate the industrial-scale manufacturing of a safe vaccine to meet global demand.
The data, presented at the 9th Conference on Retroviruses and Opportunistic Infections in Seattle, show that the vaccine for both the prevention and treatment of HIV was generally well-tolerated by the healthy volunteers enrolled in the study and generated a substantial and prolonged specific T cell response. In comparison to vaccinations with naked DNA, the adenovirus-based vaccine showed a stronger anti-HIV immune response.
Merck & Co. has stressed that the data are preliminary and inconclusive as the phase I trial is still ongoing and that it is too early to speculate on when data of the entire phase I trial will be presented. Last month, Merck & Co. released data showing that monkeys that had been given the vaccine did not develop AIDS after being infected with an HIV-like virus. According to UNAIDS, five million people were infected with HIV in 2001, bringing the total number of people living with HIV to 40 million.
Crucell's CEO Dinko Valerio said that though the results are preliminary and inconclusive, research is on the right track. "The data further confirm that Merck & Co.'s adenovirus-based HIV vaccine is one of the most promising candidates to date. Crucell ...
- Crucell: Preliminary Phase I Data of PER.C6-derived HIV Vaccine Encouraging.
- Press release article from: PR Newswire March 5, 2002 700+ words
...s experimental HIV vaccine look encouraging. The HIV vaccine, based on a recombinant...is produced on Crucell's proprietary PER...adenovirus-based HIV vaccine is one of the most...candidates to date. Crucell is proud to have...
- Crucell gets $16.2M NIH contract for HIV vaccine project.
- Newspaper article from: Pharma Marketletter October 16, 2006 700+ words
...clinical trials. Further, the NIAID HIV Vaccine Trials Network has expressed interest...clinical lot is available, said Crucell. Jaap Goudsmit, Crucell's chief...the safe, effective and accessible HIV vaccine that the world needs so urgently...
- Dutch Crucell reports good results with HIV vaccine.(Financial report)
- News wire article from: ADP News Netherlands October 22, 2009 700+ words
...Phase I study of its HIV vaccine. According to Crucell, the preliminary results...immunogenic. In April 2008, Crucell announced the start of...the novel recombinant HIV vaccine. The vaccine is based on Crucell's AdVac and PER.C6...
- Crucell's PER.C6 Cell-Line Used in Merck's HIV-1 Vaccines Research Program.
- Press release article from: PR Newswire April 3, 2001 700+ words
...commercial license to Crucell's PER.C6 platform...application of PER.C6 in HIV vaccine development. The agreement...payments paid by Merck to Crucell, and further provides...develop its experimental HIV-vaccine. This is an important agreement for Crucell as it is our first ...
- Crucell Appoints VP Development and Regulatory Affairs.
- Press release article from: PR Newswire January 17, 2002 700+ words
...its experimental HIV vaccine, which is produced on PER.C6. Crucell's CEO Dinko Valerio...every single year. Crucell also plays an essential...Merck & Co's HIV vaccine. Merck &...exclusive rights to use Crucell's PER.C6 human...
- Crucell and Innogenetics Announce PER.C6 Deal for the Development And...
- Press release article from: PR Newswire January 23, 2002 700+ words
...antibodies every single year. Crucell also plays an essential...Merck & Co's HIV vaccine. Merck & Co has...exclusive rights to use Crucell's PER.C6 human cell...II trials with its HIV vaccine. The company has furthermore...
- Crucell Announces First Quarter Results.
- Press release article from: PR Newswire May 8, 2001 700+ words
...President and Chief Executive Officer of Crucell. "We signed up a new PER.C6 licensee...early clinical trials with their HIV vaccine in February that was produced using...exclusive license agreement with Crucell. * Executed a licensing agreement...
- Lexigen Signs On as Crucell's 19th PER.C6 Licensee.
- Press release article from: PR Newswire January 15, 2002 700+ words
...safety qualities." Crucell's nineteen PER.C6...produce its experimental HIV vaccine. Multiple vaccine and...every single year. Crucell also plays an essential...Merck & Co's HIV vaccine. Merck & Co has...exclusive rights to use Crucell's PER.C6 human cell...
Source: HighBeam Research, Preliminary phase I data of PER.C6-derived HIV vaccine...